Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

376 17 Immunotoxins and Recombinant Immunotoxins in Cancer Therapy
lymphomas resistant to conventional
therapy. Blood 82: 2624±33.
130 Sausville EA, Headlee D, Stetler-
Stevenson M, et al. (1995) Continuous
infusion of the anti-CD22 immunotoxin
IgG±RFB4±SMPT±dgA in patients
with B-cell lymphoma: a phase I
study. Blood 85: 3457±65.
131 Senderowicz AM,Vitetta E, Headlee
D, et al. (1997) Complete sustained
response of a refractory post-transplantation,
large B-cell lymphoma to an
anti-CD22 immunotoxin. Ann Intern
Med 126: 882±5.
132 Scheuermann RH, Racila E (1995)
CD19 antigen in leukemia and lymphoma
diagnosis and immunotherapy.
Leuk Lymph 18: 385±97.
133 Stone MJ, Sausville EA, Fay LW, et al.
(1996) A phase I study of bolus versus
continuous infusion of the anti-CD19
immunotoxin, IgG±HD37±dgA, in patients
with B-cell lymphoma. Blood 88:
1188±97.
134 Conry RM, Khazaeli MB, Saleh MN,
et al. (1995) Phase I trial of an anti-
CD19 deglycosylated ricin A chain immunotoxin
in non-Hodgkin's lymphoma:
effect of an intensive schedule
of administration. J Immunother 18:
231±41.
135 Multani PS, O'Oay S, Nadler LM,
Grossbard ML (1998) Phase II clinical
trial of bolus infusion anti-B4 blocked ricin
immunoconjugate in patients with
relapsed B-cell non-Hodgkin's lymphoma.
Clin Cancer Res 4: 2599±604.
136 LeMaistre CF, Saleh MN, Kuzel TM,
et al. (1998) Phase I trial of a ligand fusion-protein
(DAB389IL-2) in lymphomas
expressing the receptor for interleukin-2.
Blood 91: 399±405.
137 Re GG,Waters C, Poisson L, Willingham
MC, Sugamura K, Frankel AE
(1996) Interleukin 2 (lL-2) receptor expression
and sensitivity to diphtheria
fusion toxin DAB(389) lL-2 in cultured
hematopoietic cells. Cancer Res 56:
2590±5.
138 Waters CA, Schimke PA, Snider CE,
et al. (1990) Interleukin 2 receptor-targeted
cytotoxicity. Receptor binding requirements
for entry of a diphtheria
toxin-related interleukin 2 fusion pro-
tein into cells. Eur J Immunol 20: 785±
91.
139 Ouvic M, Kuzel T, Olsen E, et al.
(1998) Quality of life is significantly improved
in CTCl patients who responded
to DAB3891l-2 (ONTAK) fusion protein.
Blood 92 (suppl 1): 2572.
140 Hudson PJ (1999) Recombinant antibody
constructs in cancer therapy. Curr
Opin Immunol 11: 548±57.
141 Hudson PJ (2000) Recombinant antibodies:
a novel approach to cancer diagnosis
and therapy. Exp Opin Invest
Drugs 9: 1231±42.
142 Smith GP (1985) Filamentous fusion
phage: novel expression vectors that
display cloned antigens on the virion
surface. Science 228: 1315±7.
143 Orlandi R, Gussow DH, Jones PT,
Winter G (1989) Cloning immunoglobulin
variable domains for expression
by the polymerase chain reaction. Proc
Natl Acad Sci USA 86: 3833±7.
144 Chiang YL, Sheng-Dong R, Brow MA,
Larrick JW (1989) Direct cDNA cloning
of the rearranged immunoglobulin variable
region. Biotechniques 7: 360±6.
145 Ward ES, Gussow D, Griffiths AD,
Jones PT,Winter G (1989) Binding activities
of a repertoire of single immunoglobulin
variable domains secreted
from Escherichia coli. Nature 341: 544±6.
146 Huse WD, Sastry L, Iverson SA, et al.
(1989) Generation of a large combinatorial
library of the immunoglobulin repertoire
in phage lambda. Science 246:
1275±81.
147 Better M, Chang CP, Robinson RR,
Horwitz AH (1988) Escherichia coli secretion
of an active chimeric antibody
fragment. Science 240: 1041±3.
148 Skerra A, Pluckthun A (1988) Assembly
of a functional immunoglobulin
Fv fragment in Escherichia coli.
Science 240: 1038±41.
149 McCafferty J, Griffiths AD, Winter
G, Chiswell DJ (1990) Phage antibodies:
filamentous phage displaying
antibody variable domains. Nature 348:
552±4.
150 Hoogenboom HR, Griffiths AD,
Johnson KS, Chiswell DJ, Hudson P,
Winter G (1991) Multi-subunit proteins
on the surface of filamentous